BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1

About this update from Betterlife Pharma Inc.

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is a potent neuroplastogen and an agonist of the 5-HT1B, 5-HT1D, and 5-HT1F receptors, which are clinically validated targets of migraine therapies, as well as the 5-HT2A receptors. BETR-001 is being developed initially for migraine and cluster headache, two disabling headache disorders with substantial unmet medical needs. The BETR-001 IND filing is projected for Q1 2027. "We are pleased to be partnering with Nucro to conduct the final BETR-001 IND-enabling GLP toxicology study. Their toxicology and regulatory expertise strengthen our path to an IND filing in the first quarter of 2027," said Dr. Ahmad Doroudian, BetterLife's Chief Executive Officer. "We are pleased to partner with BetterLife to advance BETR-001 toward the clinic through design and conduct of the final IND-enabling GLP toxicology study. Our teams share a commitment to advancing innovative therapies efficiently and responsibly, with the goal of bringing new treatment options to patients. We are proud to support this program as it progresses toward IND submission and first-in-human clinical studies, "said John Fanaras, President of Nucro. About BetterLife Pharma BetterLife Pharma Inc. is a biotechnology company developing compounds for the treatment of neurological and neuro-psychiatric disorders. Its lead candidate, BETR-001, is a non-hallucinogenic LSD-derivative molecule in preclinical development. For further information, please visit BetterLife Pharma. Contact Ahmad Doroudian, Chief Executive OfficerEmail: [email protected]: 1-604-221-0595 About Nucro-Technics Nucro-Technics Inc. is a Pharmaceutical Contract Support Organization and conducts GMP & GLP-Compliant Chemistry, Microbiology, Toxicology, Genetic Toxicology, and Bioanalytical Testing to fulfill FDA, Health Canada, European and other International Regulatory Agencies. For further information, please visit Nucro-Technics. Contact John C. Fanaras, Presid...

View stock analysis, news, and events for Betterlife Pharma Inc.